Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001100007 |
Resumo: | The biologic basis of the negative prognosis of plasmablastic myeloma is not fully understood. To determine whether histologically aggressive multiple myeloma (MM) is associated with a more angiogenic marrow environment, bone marrow samples from 50 recently diagnosed MM patients were evaluated. Twelve percent (6/50) of patients presented plasmablastic MM, and this feature correlated with moderate/strong intensity of vascular endothelial growth factor staining of plasma cells (P = 0.036). Although plasmablastic MM was not associated with increasing of microvessel density, this new evidence of increased expression of vascular endothelial growth factor on plasmablasts suggests that the adverse prognosis conferred by plasmablastic disease may be due, at least in part, to secretion of this angiogenic cytokine, also suggesting that the subset of MM patients with plasmablastic features may derive particular benefit from antiangiogenic therapies. |
id |
ABDC-1_b61402936317c04ea78dad3ad31c5c58 |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X2005001100007 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpressionMultiple myelomaAngiogenesisVascular endothelial growth factorThe biologic basis of the negative prognosis of plasmablastic myeloma is not fully understood. To determine whether histologically aggressive multiple myeloma (MM) is associated with a more angiogenic marrow environment, bone marrow samples from 50 recently diagnosed MM patients were evaluated. Twelve percent (6/50) of patients presented plasmablastic MM, and this feature correlated with moderate/strong intensity of vascular endothelial growth factor staining of plasma cells (P = 0.036). Although plasmablastic MM was not associated with increasing of microvessel density, this new evidence of increased expression of vascular endothelial growth factor on plasmablasts suggests that the adverse prognosis conferred by plasmablastic disease may be due, at least in part, to secretion of this angiogenic cytokine, also suggesting that the subset of MM patients with plasmablastic features may derive particular benefit from antiangiogenic therapies.Associação Brasileira de Divulgação Científica2005-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001100007Brazilian Journal of Medical and Biological Research v.38 n.11 2005reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2005001100007info:eu-repo/semantics/openAccessRibas,C.Colleoni,G.W.B.Almeida,M.S.S.Aguiar,K.C.C.Silva,M.R.R.Bordin,J.O.eng2005-10-26T00:00:00Zoai:scielo:S0100-879X2005001100007Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2005-10-26T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
title |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
spellingShingle |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression Ribas,C. Multiple myeloma Angiogenesis Vascular endothelial growth factor |
title_short |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
title_full |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
title_fullStr |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
title_full_unstemmed |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
title_sort |
Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression |
author |
Ribas,C. |
author_facet |
Ribas,C. Colleoni,G.W.B. Almeida,M.S.S. Aguiar,K.C.C. Silva,M.R.R. Bordin,J.O. |
author_role |
author |
author2 |
Colleoni,G.W.B. Almeida,M.S.S. Aguiar,K.C.C. Silva,M.R.R. Bordin,J.O. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Ribas,C. Colleoni,G.W.B. Almeida,M.S.S. Aguiar,K.C.C. Silva,M.R.R. Bordin,J.O. |
dc.subject.por.fl_str_mv |
Multiple myeloma Angiogenesis Vascular endothelial growth factor |
topic |
Multiple myeloma Angiogenesis Vascular endothelial growth factor |
description |
The biologic basis of the negative prognosis of plasmablastic myeloma is not fully understood. To determine whether histologically aggressive multiple myeloma (MM) is associated with a more angiogenic marrow environment, bone marrow samples from 50 recently diagnosed MM patients were evaluated. Twelve percent (6/50) of patients presented plasmablastic MM, and this feature correlated with moderate/strong intensity of vascular endothelial growth factor staining of plasma cells (P = 0.036). Although plasmablastic MM was not associated with increasing of microvessel density, this new evidence of increased expression of vascular endothelial growth factor on plasmablasts suggests that the adverse prognosis conferred by plasmablastic disease may be due, at least in part, to secretion of this angiogenic cytokine, also suggesting that the subset of MM patients with plasmablastic features may derive particular benefit from antiangiogenic therapies. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001100007 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001100007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0100-879X2005001100007 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.38 n.11 2005 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302934201401344 |